CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AbbVie Inc. v. Amneal Pharmaceuticals, LLC

1:16-cv-00398

Overview

Case Number 1:16-cv-00398
Filing Date 2016-05-27
Status Terminated
Termination Date 2016-09-06
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Amneal Pharmaceuticals of New York, LLC Operating Company

Represented By

2 Attorneys Listed

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Amneal Pharmaceuticals, LLC Operating Company

Represented By

2 Attorneys Listed

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

AbbVie Inc. Operating Company

Represented By

3 Attorneys Listed

Stephen J. Kraftschik

Polsinelli PC

Tel: +1 (302) 252-0926
Fax: +1 (302) 252-0921

222 Delaware Avenue, Suite 1101, Wilmington, DE 19801

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Mary B. Graham

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 7 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (7 found):
U.S. Courts: 7
U.S. District Court 2017-01-13
1:17-cv-00047

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2015-10-02
1:15-cv-00889

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-07-18
1:14-cv-00959

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2013-07-03
2:13-cv-00645

AbbVie Inc. v. Roxane Laboratories Inc.

Asserted Patent
Status: OHSD
U.S. District Court 2013-06-14
1:13-cv-01072

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-05-15
1:13-cv-00852

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-04-10
1:12-cv-00457

AbbVie Inc. v. Roxane Laboratories Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7148359
Polymorph of a pharmaceutical
Filed: 2005-05-04
Issued: 2006-12-12
Expired (Term Ended)
Expires: 2025-05-04
US7364752
Solid dispersion pharamaceutical formulations
Filed: 2000-11-10
Issued: 2008-04-29
Expired (Term Ended) +688d PTA
Expires: 2022-09-29

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(14 total)
Pleading / Complaint

COMPLAINT filed against Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1938613.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(sar) (Entered: 05/31/2016)

Entry #1 • 2016-05-27
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sar) (Entered: 05/31/2016)

Entry #2 • 2016-05-27
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 15, 2016. Date of Expiration of Patent: Patent No. 7,148,359: July 19, 2019 with an extension for pediatric exclusivity until: January 19, 2020 Patent No. 7,364,752: November 10, 2020 with an extension for pediatric exclusivity until: May 10, 2021.Thirty Month Stay Deadline: 10/15/2018. (sar) (Entered: 05/31/2016)

Entry #3 • 2016-05-27
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,148,359 B2; 7,364,752 C1;. (sar) (Entered: 05/31/2016)

Entry #4 • 2016-05-27
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc.. (sar) (Entered: 05/31/2016)

Entry #5 • 2016-05-27
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc